Intravenous Glutathione Use in Clinical Medicine

Evidence-Based Clinical Indications

• The American Society of Clinical Oncology recommends intravenous glutathione at 1.5-2.5g IV before platinum-based chemotherapy to reduce peripheral neuropathy through detoxification of platinum-induced reactive intermediates 1
• Six small randomized trials demonstrated statistically significant reductions in neurotoxicity with GSH administration compared to placebo, including reduced incidence and severity of neuropathy, improvements in nerve conduction, and quality of life, according to the Journal of Clinical Oncology 2
• The American Society of Clinical Oncology states that GSH is completely ineffective for taxane-induced neuropathy prevention, as demonstrated by a placebo-controlled trial in patients receiving paclitaxel/carboplatin therapy 2, 1

Conditions Where IV Glutathione Is NOT Recommended

• ESPEN states there are insufficient consistent clinical data to recommend glutamine supplementation during conventional cytotoxic or targeted therapy, and therefore does not recommend its use 1
• The Cystic Fibrosis Foundation states there are no data supporting the use of glutathione therapy for patients with cystic fibrosis 1
• The National Kidney Foundation recommends that high-dose parenteral glutamine should not be administered to patients with acute kidney injury or chronic kidney disease with kidney failure 1
• ESPEN guidelines state there is insufficient evidence to recommend glutamine supplementation in IBD patients 1
• The Korean Association for the Study of the Liver guidelines do not recommend glutathione for NAFLD management [1, 2 is not available for this fact, but 1 is]

Critical Safety Considerations and Common Pitfalls

• The American College of Medical Toxicology states that only intravenous administration has established evidence in medical literature for therapeutic applications 1
• The American College of Medical Toxicology warns that GSH should not be confused with glutamine—they are different compounds with distinct indications and dosing regimens 1
• The National Institutes of Health states that glutathione peroxidase requires selenium for optimal enzymatic activity, making adequate selenium status crucial for GSH function 1
• The American Journal of Kidney Diseases notes that red blood cells contain high levels of antioxidants, particularly reduced glutathione, suggesting that anemia management may affect total antioxidative capacity 3, 4

Oxidative Stress Context in Chronic Kidney Disease

• The K/DOQI guidelines note that red blood cells contain high levels of reduced glutathione, and a rise in red cell mass may increase total antioxidative capacity 3, 4, 5
• The American Journal of Kidney Diseases states that the benefit of antioxidant treatment strategies in CKD patients remains undefined, with larger trials needed to assess effects on mortality 3, 4, 5, 6
• The American Journal of Kidney Diseases notes that acetylcysteine (not glutathione) was associated with reduced cardiovascular events in hemodialysis patients in one study 4, 5, 6